---
title: Treatment of MDR Gram-negative bacilli
date:
  created: 2025-03-06T15:25:16
  updated: 2025-03-10T17:29:32
tags: share
share: true
categories:
  - medicine
  - abx
alias: mdr-gnb
status: finished
---
# Treatment of MDR Gram-negative bacilli  
  
![f3b5d87da5acf2c8d79ff55edb954115_MD5.jpeg](../assets/f3b5d87da5acf2c8d79ff55edb954115_MD5.jpeg)  
> Green, susceptibility anticipated to be >80%; yellow, susceptibility anticipated to be 30% to 80%; red, intrinsic resistance or susceptibility anticipated to be <30%. 1, US Food and Drug Administration–approved agent; 2, synthetic tetracycline derivative; 3, imipenem-cilastatin–relebactam; 4, synthetic aminoglycoside; 5, polymyxin class. Abbreviations: KPC, Klebsiella pneumoniae carbapenemase; NDM, New Delhi metallo-β-lactamase. (Tamma et al., 2024)  
  
<!-- more -->  
  
## ESBL  
- ==Carbapenem==  
- Fluoroquinolone (UTI)  
- TMP-SMX (UTI)  
- Aminoglycoside (UTI)  
- Fosfomycin (uncomplicated cystitis, E. coli only)  
- Pip/tazo (uncomplicated cystitis, clinically improving)  
- Cefepime (uncomplicated cystitis, clinically improving)  
  
## AmpC β-lactamase  
- ==Cefepime==  
- TMP-SMX (UTI)  
- Fluoroquinolone (UTI)  
- Single-dose aminoglycoside (uncomplicated cystitis)  
- Ceftriaxone (uncomplicated cystitis)  
  
## CRE  
### R to ertapenem only  
- Extended-infusion meropenem or imipenem/cilastatin  
### UTI  
- TMP-SMX  
- Fluoroquinolone  
- Aminoglycoside  
- ==Cefiderocol==  
- ==Ceftazidime-avibactam==  
- Imipenem-cilastatin-relebactam  
- Meropenem-vaborbactam  
- Colistin (uncomplicated cystitis)   
- Fosfomycin (uncomplicated cystitis, E. coli only)  
### KPC  
- ==Ceftazidime/avibactam==  
- Imipenem-cilastatin-relebactam  
- Meropenem-vaborbactam  
- Cefiderocol  
- Minocycline (non-UTI or BSI)  
- Tigecycline (non-UTI or BSI)  
### OXA-48  
- ==Ceftazidime/avibactam==  
- Cefiderocol  
### NDM  
- ==Cefiderocol==  
- Ceftazidime/avibactam + aztreonam  
  
## CRPA  
- Extended-infusion non-carbapenem β-lactam (if S)  
- ==Ceftazidime/avibactam==  
- ==Cefiderocol==  
- Ceftolozane-tazobactam  
- Imipenem-cilastatin-relebactam  
- Aminoglycoside (UTI)  
- Colistin (uncomplicated cystitis)  
  
## CRAB  
- ==Colistin + (sulbactam or fosfomycin)==  
- High-dose minocycline (200mg Q12H)  
- High-dose tigecycline (100mg Q12H)  
- Cefiderocol（上述治療無效或沒其他藥可用時）  
- Sulbactam-durlobactam + (meropenem or imipenem/cilastatin)  
  
### Ampicillin/Sulbactam Dosage Adjustment Recommendations for Kidney Impairment when Treating Multidrug-resistant *A. baumannii* Infection  
  
| **CrCl (mL/min)** | **Traditional Intermittent Infusion** (3 g IV every 4 hours over ≤30 min) | **Extended Infusion** (9 g IV every 8 hours over 4 hours) | **Continuous Infusion** (27 g IV over 24 hours) |  
| ----------------- | ------------------------------------------------------------------------- | --------------------------------------------------------- | ----------------------------------------------- |  
| **≥90 to 130**    | No dosage adjustment necessary<sup>b</sup>                                | No dosage adjustment necessary<sup>c,d</sup>              | No dosage adjustment necessary                  |  
| **60 to <90**     | No dosage adjustment necessary<sup>b</sup>                                | 6 g IV every 8 hours over 4 hours<sup>c,d</sup>           | 18 g IV over 24 hours<sup>c</sup>               |  
| **30 to <60**     | 3 g IV every 6 hours<sup>b</sup>                                          | 3 g IV every 6 hours over 4 hours<sup>c,d</sup>           | 12 g IV over 24 hours<sup>c</sup>               |  
| **15 to <30**     | 3 g IV every 8 hours<sup>b</sup>                                          | 3 g IV every 8 hours over 4 hours<sup>c,d</sup>           | 9 g IV over 24 hours<sup>c</sup>                |  
| **<15**           | 3 g IV every 12 hours<sup>b</sup>                                         | 3 g IV every 12 hours over 4 hours<sup>e</sup>            | 6 g IV over 24 hours<sup>e</sup>                |  
  
> <sup>a</sup> The proposed renal dose adjustments are aimed at achieving pharmacokinetic/pharmacodynamic targets based on in-vitro or pharmacokinetic modeling. Clinical data are not available.    
> <sup>b</sup> Expert opinion derived from Yokoyama 2015. Doses in Yokoyama 2015 are in grams of sulbactam; the doses listed below are multiplied by 3 to account for both ampicillin and sulbactam components.    
> <sup>c</sup> Expert opinion derived from Jaruratanasirikul 2019. Doses in Jaruratanasirikul 2019 are in grams of sulbactam; the doses listed below are multiplied by 3 to account for both ampicillin and sulbactam components.    
> <sup>d</sup> Lower doses may be sufficient for patients with lower albumin concentrations (e.g., 1.7 to 2.4 g/dL) and isolates with lower minimum inhibitory concentrations. See Jaruratanasirikul 2019 for patient-specific recommendations.    
> <sup>e</sup> Expert opinion.  
  
Ref: [UpToDate](https://www.uptodate.com/contents/ampicillin-and-sulbactam-drug-information?sectionName=Kidney%20Impairment%20(Adult)&topicId=8745&search=ampicillin%2Fsulbactam&usage_type=panel&anchor=F50991106&source=panel_search_result&selectedTitle=1~82&showDrugLabel=true&kp_tab=drug_general&display_rank=1#F50991106)  
  
## *S. maltophila*  
- TMP-SMX (10–15 mg/kg TMP)  
- Levofloxacin (750mg QD)  
- High-dose minocycline (200mg Q12H)  
- Cefiderocol  
  
## Reference  
  
Tamma, P.D., Heil, E.L., Justo, J.A., Mathers, A.J., Satlin, M.J. & Bonomo, R.A. (2024) Infectious Diseases Society of America 2024 Guidance on the Treatment of Antimicrobial-Resistant Gram-Negative Infections. _Clinical Infectious Diseases_. ciae403. doi:[10.1093/cid/ciae403](https://doi.org/10.1093/cid/ciae403).  
  
   
```meta-bind-button  
label: "Upload"  
style: default  
id: "upload"  
actions:  
  - type: updateMetadata  
    bindTarget: date.updated  
    evaluate: true  
    value: moment().format("YYYY-MM-DDTHH:mm:ss")  
  - type: command  
    command: obsidian-mkdocs-publisher:share-one  
```